App-Quantinova.ai

Prevalence of proteinuria in urologic patients.

Adam Bezinque - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Comprehensive genomic characterization of clear-cell renal cell carcinomas with sarcomatoid dedifferentiation.

Ronan Flippot - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

10 year outcomes from a single-centre experience of sunitinib and pazopanib as first-line treatment of metastatic renal-cell carcinoma (mRCC).

Shien Chow - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pazopanib

Gene expression profiling of primary and metastatic renal cell carcinoma tumor initiating cells.

Anna Malgorzata Czarnecka - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Incidence of brain metastases in metastatic renal cell carcinoma in the era of targeted therapies.

I. Alex Bowman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Risk of left ventricular systolic dysfunction with sunitinib therapy in patients with metastatic renal cell carcinoma: A prospective cohort study.

Vivek Narayan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Sunitinib

Dynamic role of GTP-energy metabolism in metastasis of renal cell carcinomas: Prognosis and therapeutic applications.

Jaskirat Singh Randhawa - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Overall survival after image guided thermal ablation of pathologically proven T1a RCC in cancer survivors.

Mohamed E. Abdelsalam - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A phase I trial of cabazitaxel +/- rhenium-188-HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment.

Esther W. Bouman-Wammes - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

rhenium-188-HEDP

Psychological status and pain outcome evaluation in patients with painful bone metastases from castration resistant prostate cancer treated with 223Radium.

Viviana Frantellizzi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Radium-223 Dichloride

Clinical activity of ONC201 in metastatic castrate resistant prostate cancer (mCRPC).

Mark N. Stein - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

TIC 10

Image guided thermal ablation of prostate cancer metastases to the liver.

Bruno C. Odisio - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

11C-Choline PET guided resection of thoracic metastases from prostatic adenocarcinoma.

Justin Moser - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Choline bitartrate

Real world skeletal related events (SREs) associated with oral treatments in patients with metastatic castration resistant prostate cancer (mCRPC).

Nicole Engel-Nitz - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Docetaxel

PRO-BMI study: prognostic role of body mass index (BMI) in metastatic castration resistant prostate cancer (mCRPC) patients receiving chemotherapy.

Marcello Tucci - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Docetaxel

Open-label phase II study evaluating the efficacy of concurrent administration of radium Ra 223 dichloride and abiraterone acetate in men with castration-resistant prostate cancer patients with symptomatic bone metastases.

Luke T. Nordquist - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Radium-223 Dichloride

Prostate-specific extracellular vesicles as a novel biomarker in human prostate cancer.

Yong Hyun Park - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

PTP1B expression and Gleason Score (GS) in localized prostate cancer (PC).

Mauricio Mora Pineda - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Association of PSA and number of cores positive with likelihood of adverse pathology at radical prostatectomy based on a 17-gene expression assay.

Michael Bonham - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Irf7 as a novel marker for predicting bone metastases of primary prostate cancer.

Zhao Yang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts